- ScreenPro (SCRN) has issued a COVID-19 testing update
- The company is currently providing COVID-19 testing to 11 film production companies in Canada
- It expects greater testing revenue as the film industry returns to full force amid the increasing spread of Omicron variants
- ScreenPro Security is a medical technology company providing turnkey screening solutions through proprietary alerting software
- ScreenPro (SCRN) is unchanged, trading at $0.03 per share
ScreenPro (SCRN) has issued a COVID-19 testing update.
The company is currently providing COVID-19 testing to 11 film production companies in Canada.
It expects strong testing demand after the Screen Actors Guild-American Federation of Television and Radio Artists noted that testing will remain in place into 2023.
Canada’s COVID-19 Immunity Task Force has also suggested that infections rise in the colder seasons, which may be exacerbated by the spread of more resilient Omicron variants.
“The company is proud to do its part in aiding in the health and safety of the community and continue our relationship with the film and production industry,” stated Andrew Ryu, ScreenPro’s Chairman and CEO. “As film productions ramp up, the company expects to see an increase in COVID-19 testing contracts due to steady demand.”
ScreenPro Security is a medical technology company providing turnkey screening solutions through proprietary alerting software.
ScreenPro (SCRN) is unchanged, trading at $0.03 per share as of 3:05 pm EST.
